Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

United Therapeutics (UTHR) Gross Margin (2016 - 2025)

United Therapeutics' Gross Margin history spans 17 years, with the latest figure at 86.91% for Q4 2025.

  • For Q4 2025, Gross Margin changed N/A year-over-year to 86.91%; the TTM value through Dec 2025 reached 87.92%, changed N/A, while the annual FY2025 figure was 87.92%, 131.0% down from the prior year.
  • Gross Margin for Q4 2025 was 86.91% at United Therapeutics, down from 87.38% in the prior quarter.
  • Across five years, Gross Margin topped out at 94.39% in Q1 2022 and bottomed at 7000.0% in Q4 2023.
  • The 5-year median for Gross Margin is 89.24% (2024), against an average of 282.83%.
  • The largest annual shift saw Gross Margin skyrocketed 197bps in 2022 before it crashed -708804bps in 2023.
  • A 5-year view of Gross Margin shows it stood at 91.67% in 2021, then dropped by -4bps to 88.04% in 2022, then plummeted by -8051bps to 7000.0% in 2023, then skyrocketed by 101bps to 88.9% in 2024, then fell by -2bps to 86.91% in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Gross Margin are 86.91% (Q4 2025), 87.38% (Q3 2025), and 89.03% (Q2 2025).